Study identifier:SH-TPA-0004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Long-Term Treatment with the Oral Direct Thrombin Inhibitor Ximelagatran, Compared to Warfarin, as Stroke Prophylaxis in Patients with Atrial Fibrillation. A long term follow-Up Study
Stroke prevention in patients with atrial fibrillation
Phase 2
No
EXANTA
All
220
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin.
Location
Location
Oostduinkerke, Belgium
Location
Most, Czech Republic
Location
Poibram, Czech Republic
Location
Prague, Czech Republic
Location
Plzeo, Czech Republic
Location
Odense, Denmark
Location
Arhus, Denmark
Location
Helsingor, Czech Republic
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.